Well Said African Trader!
100% CORRECT!
That is how Valuation was determined by Gilead Sciences when they bought Kite for $11.9 Billion in 2017 and that was based on the only Patent Kite had at that time that was mRNA based AND it had not yet been FDA approved for entering clinical trials.
This should speak volumes to all share holders of RGBP due having 24 Patents that includes mRNA Vaccine Biotechnology especially in light of the advancements in mRNA Vaccines that have gone global for Covid-19 via Pfizer, Moderna, etc. This is now the BIGGEST MARKET in the entire Pharmaceutical Industry and everyone wants a piece of that Trillion Dollar Global Market Share.
There are people that think a Buy Out of RGBP will be based solely on its current pps. This is an absurd & ridiculous notion.
Candidate Drug Patent Valuation is always based on the merit, validity, and therapeutic application of the science AND the projected Market Valuation.Then typically there's a premium added to the current PPS ALL of which was exactly the case when Gilead bought Kite. These elements are not different when buy out value determination is made for ANY Pharmaceutical Company.
It will be NO DIFFERENT when RGBP is bought out IF that happens, and that is a very high probability! Thus the reason for Dr. Koos filing that 8K on 4/27/21, i.e. his's NOT going to allow RGBP to be bought out from under him without a say in the purchase price and because of that 8K his voice in fact will be the only one that determines what offers will and won't be accept. This point should cause lights to go on in everyone's thinking. This man is highly intelligent and experienced in this industry and that 8K protects his "golden goose" and guarantees him to get the PRICE he wants for this company and it's going to be a whopping price tag!...again IF a Buy Out occurs!
Just imagine what the Buy Out offer would be on RGBP due to holding not ONE (1) but TWENTY FOUR (24) Disruptive Biotechnology Patents that includes mRNA vaccine biotechnology for treating pancreatic & colon cancer. The Combined Value of RGBP's Patents are absolutely astronomical.
In closing, let me say this, IF I was on the Advisory Board of any of the Big Pharmas I listed, I will tell the CEO that he/she would be insane if they didn't immediately BUY/Acquire RGBP, and here' the reality; these CEO's already know that if they don't buy RGBP another Big Pharma will and if that happens they will have missed an opportunity to expand their therapeutic portfolio, in particular in the area of mRNA based vaccines, AND a chance to OWN THE SCIENCE that went into all 24 of RGBP's Patents that are ALL Candidate Drug Patents.
It's going to be very interesting to see what happens in the very near future once we go Pink Current and Koos accomplishes renewing ALL of RGBP's Patents.
My personal take on this and prediction is there's going to be a BIDDING WAR over RGBP, so anyone holding shares in this company I would advise to hold tight those shares and those who haven't opened a position in RGBP has better do that soon or they will miss a once in a lifetime opportunity at wealth building.
Be well and prosper...
